Compare ICUI & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICUI | TWST |
|---|---|---|
| Founded | 1984 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.0B |
| IPO Year | 1995 | 2018 |
| Metric | ICUI | TWST |
|---|---|---|
| Price | $137.48 | $70.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $169.00 | $46.88 |
| AVG Volume (30 Days) | 271.7K | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.62 | 63.89 |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $2,231,262,000.00 | $376,572,000.00 |
| Revenue This Year | N/A | $18.91 |
| Revenue Next Year | $4.46 | $15.07 |
| P/E Ratio | $113.84 | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $107.02 | $23.30 |
| 52 Week High | $160.29 | $80.50 |
| Indicator | ICUI | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 63.52 | 60.64 |
| Support Level | $115.74 | $41.85 |
| Resistance Level | $142.31 | N/A |
| Average True Range (ATR) | 4.76 | 4.84 |
| MACD | 0.63 | 0.89 |
| Stochastic Oscillator | 81.81 | 63.30 |
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.